182 related articles for article (PubMed ID: 33658859)
1. MRPL13 Promotes Tumor Cell Proliferation, Migration and EMT Process in Breast Cancer Through the PI3K-AKT-mTOR Pathway.
Cai M; Li H; Chen R; Zhou X
Cancer Manag Res; 2021; 13():2009-2024. PubMed ID: 33658859
[TBL] [Abstract][Full Text] [Related]
2. MRPL13 is a Prognostic Cancer Biomarker and Correlates with Immune Infiltrates in Breast Cancer.
Tao Z; Suo H; Zhang L; Jin Z; Wang Z; Wang D; Wu M; Peng N; Zhao Y; Chen B
Onco Targets Ther; 2020; 13():12255-12268. PubMed ID: 33273831
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis of MRPL-13 as a tumor-promoting marker from pan-cancer to lung adenocarcinoma.
Zhong X; He Z; Fan Y; Yin L; Hong Z; Tong Y; Bi Q; Zhu S
Aging (Albany NY); 2023 Oct; 15(19):10640-10680. PubMed ID: 37827692
[TBL] [Abstract][Full Text] [Related]
4. [High expression of MRPL13 promotes cell cycle progression and proliferation of gastric cancer cells by inhibiting p53 signaling to affect long-term prognosis].
Wang L; Xia Y; Zhang Z; Liu X; Shi J; Wang Y; Li J; Zhnag X; Geng Z; Song X; Zuo L
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1558-1566. PubMed ID: 37814870
[TBL] [Abstract][Full Text] [Related]
5. Long-Chain Non-Coding SOX21-AS1 Promotes Proliferation and Migration of Breast Cancer Cells Through the PI3K/AKT Signaling Pathway.
Sheng XY; Wang CH; Wang CF; Xu HY
Cancer Manag Res; 2020; 12():11005-11014. PubMed ID: 33173334
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognosis analysis of mitochondrial ribosomal protein family in breast cancer.
Lin X; Guo L; Lin X; Wang Y; Zhang G
Sci Rep; 2022 Jun; 12(1):10658. PubMed ID: 35739158
[TBL] [Abstract][Full Text] [Related]
7. MRPL13 Act as a Novel Therapeutic Target and Could Promote Cell Proliferation in Non-Small Cell Lung Cancer.
Jing C; Fu R; Wang C; Li X; Zhang W
Cancer Manag Res; 2021; 13():5535-5545. PubMed ID: 34285575
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer.
Ye H; Zhang N
Comput Math Methods Med; 2021; 2021():1498924. PubMed ID: 34868337
[TBL] [Abstract][Full Text] [Related]
9. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
Xu JH; Wang Y; Xu D
Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
[TBL] [Abstract][Full Text] [Related]
10. AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway.
Qu J; Li J; Zhang Y; He R; Liu X; Gong K; Duan L; Luo W; Hu Z; Wang G; Xia C; Luo D
Cell Biosci; 2021 Aug; 11(1):163. PubMed ID: 34419144
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer.
Tian X; Wu L; Jiang M; Zhang Z; Wu R; Miao J; Liu C; Gao S
Front Oncol; 2021; 11():641399. PubMed ID: 33968740
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer.
Ni J; Peng Y; Yang FL; Xi X; Huang XW; He C
Onco Targets Ther; 2018; 11():3303-3312. PubMed ID: 29892197
[TBL] [Abstract][Full Text] [Related]
14.
Li Y; Wang W; Wu X; Ling S; Ma Y; Huang P
Ann Transl Med; 2021 May; 9(10):892. PubMed ID: 34164526
[TBL] [Abstract][Full Text] [Related]
15. STIL Promotes Tumorigenesis of Bladder Cancer by Activating PI3K/AKT/mTOR Signaling Pathway and Targeting C-Myc.
Yu H; Chen L; Wang X; Tang F; Wan Z; Wang H; Fu Q; Chen Z; Shi J; Hu X; Zuhaer Y; Aersi M; Liu T; Tao H; Peng J
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497260
[TBL] [Abstract][Full Text] [Related]
16. LHX6 inhibits the proliferation, invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway.
Bi QJ; Men XJ; Han R; Li GL
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3067-3073. PubMed ID: 29863252
[TBL] [Abstract][Full Text] [Related]
17. The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway.
Yunwen C; Shanshan G; Zhifei B; Saijun C; Hua Y
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33899120
[TBL] [Abstract][Full Text] [Related]
18. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
19. C19orf10 promotes malignant behaviors of human bladder carcinoma cells via regulating the PI3K/AKT and Wnt/β-catenin pathways.
Li S; Mao L; Zhao F; Yan J; Song G; Luo Q; Li Z
J Cancer; 2021; 12(14):4341-4354. PubMed ID: 34093834
[No Abstract] [Full Text] [Related]
20. ClpP regulates breast cancer cell proliferation, invasion and apoptosis by modulating the Src/PI3K/Akt signaling pathway.
Luo J; Zeng B; Tao C; Lu M; Ren G
PeerJ; 2020; 8():e8754. PubMed ID: 32195060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
